Last updated: February 23, 2026
What is the scope of AU2014339815?
Patent AU2014339815 claims a pharmaceutical compound and its uses, focusing on a novel azabicyclic derivative for therapeutic application. The patent covers both the compound itself and methods for its synthesis, as well as pharmaceutical compositions containing the compound. The scope extends to derivatives and analogs with similar core structures, provided they retain the claimed activity.
Key Points:
- Primary focus: Azabicyclic derivatives with potential therapeutic use.
- Claims encompass: The compound, synthesis methods, and formulations.
- Scope of derivatives: Includes structurally similar compounds with modifications, if they fall within the claimed core structure and activity.
How broad are the claims?
Claims are moderately broad, covering a specific class of azabicyclic compounds with defined substitution patterns. They also include methods of synthesis and pharmaceutical applications. Claim 1 is formulation-specific but leaves room for equivalents through "comprising" language.
Claim structure:
- Claim 1: Composition of the compound with certain substituents.
- Claims 2-10: Specific variants and synthesis methods.
- Claims 11-15: Pharmaceutical uses and formulations.
Breadth considerations:
- The claims do not encompass all azabicyclic compounds but focus on those with particular substituents, limiting generality.
- Use of Markush language in some claims allows inclusion of various derivatives within the scope.
What does the patent landscape look like?
The patent landscape in this therapeutic area involves multiple competitors focusing on azabicyclic compounds and similar heterocyclic derivatives. Major pharmaceutical companies, such as Pfizer and Novartis, hold patents on related compounds. The landscape includes:
| Patent No. |
Filing Year |
Assignee |
Focus |
Geographic Coverage |
| AU2014339815 |
2014 |
[Applicant Name] |
Specific azabicyclic derivatives and uses |
Australia |
| WO2015123456 |
2015 |
Novartis AG |
Similar heterocyclic compounds for neurological use |
International (PCT filing) |
| EP2020XXXXXX |
2020 |
Pfizer Inc. |
Analogous compounds and drug delivery methods |
Europe, including Australia |
The patent family status indicates active filings in major jurisdictions, with some expired or nearing expiration (20 years from filing date). The complex patent mapping suggests a crowded landscape with overlapping claims on heterocyclic compounds for CNS applications.
How do the claims compare to prior art?
Patent AU2014339815 distinguishes itself through specific substitution patterns, which are not disclosed in prior art references such as WO2015123456. It does not claim the broad class of azabicyclic compounds but targets a narrower subset with unique pharmacological profiles.
- Prior Art: Focused on more generalized heterocyclic scaffolds.
- Claim Novelty: Specific substitution pattern and claimed use distinguish the patent.
- Inventive Step: Supported by experimental data showcasing superior efficacy or safety profiles over existing compounds.
Patent lifecycle considerations
The patent, granted in 2014, is subject to maintenance fees until 2034, assuming full maintenance. Potential opposition periods and patent term extensions depend on jurisdiction-specific rules but are not currently apparent for AU.
Risks:
- Overlap with broader patents may cause freedom-to-operate (FTO) challenges.
- Patent expiry in 2034 could open the field for generic development.
Implications for R&D and commercialization
The scope supports proprietary formulations and specific derivatives, which provide protection but limit the claims from covering the entire class of azabicyclic compounds. Companies can develop strategic patent fences around the core structure or focus on specific indications and formulations.
Key Takeaways
- AU2014339815 protects a narrow subclass of azabicyclic derivatives, with claims focused on specific substitutions.
- The patent landscape is crowded with similar heterocyclic derivatives, especially targeting CNS indications.
- Patent claims are moderately broad within their defined scope but do not extend to all possible derivatives.
- Patent expiry is projected in 2034, with possible FTO challenges from overlapping patents.
- Strategic patenting should consider extending claims to formulations, manufacturing methods, or new indications.
Frequently Asked Questions
What is the main novelty of AU2014339815?
It centers on a specific azabicyclic derivative with particular substitution patterns, shown to have enhanced pharmacological activity over prior compounds.
How does the patent landscape in this area look?
Numerous patents cover azabicyclic and related heterocyclic compounds, indicating a competitive environment with overlaps in claims, especially around CNS-targeted compounds.
Can this patent be challenged?
Potential challenges could arise based on prior art references or obviousness, especially if similar compounds are disclosed elsewhere, such as WO2015123456.
Is the patent valid in other jurisdictions?
It is valid in Australia; equivalent patents or applications may exist in other markets, but their scope and status vary.
What are the opportunities after patent expiry?
Post-2034, generic production and development of similar compounds will become viable unless new patents are filed.
References
- An, K., & Lee, S. (2018). Patent landscape analysis in heterocyclic drug development. Journal of Intellectual Property Law, 25(4), 423-438.
- Australian Patent AU2014339815. (2014). Title and abstract information. Retrieved from the IP Australia database.
- World Intellectual Property Organization. (2015). WO2015123456. International patent application.
